Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma

Clin Colorectal Cancer. 2006 Sep;6(3):229-34. doi: 10.3816/CCC.2006.n.042.
No abstract available

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols*
  • Bevacizumab
  • Clinical Trials, Phase III as Topic
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / enzymology
  • Fluorouracil / administration & dosage
  • Humans
  • Leucovorin / administration & dosage
  • Methylenetetrahydrofolate Reductase (NADPH2) / metabolism
  • Multicenter Studies as Topic
  • Neoplasm Metastasis
  • Organoplatinum Compounds
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Thymidylate Synthase / metabolism
  • Vitamin B Complex / administration & dosage

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antimetabolites, Antineoplastic
  • Organoplatinum Compounds
  • Vitamin B Complex
  • Bevacizumab
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Thymidylate Synthase
  • Leucovorin
  • Fluorouracil

Supplementary concepts

  • Folfox protocol